ストックスクリーナーアプリを入手
20.49
3.28%
0.65
プレマーケット:
20.66
0.17
+0.83%
前日終値:
$19.84
開ける：
$19.84
24時間の取引高:
666.22K
Relative Volume:
1.46
時価総額：
$910.84M
収益：
$10.32M
当期純損益:
$-89.93M
株価収益率:
-8.5148
EPS:
-2.4064
ネットキャッシュフロー:
$-88.63M
1週間 パフォーマンス:
+29.68%
1か月 パフォーマンス:
+16.02%
6か月 パフォーマンス:
+63.79%
1年 パフォーマンス:
+367.81%
1日の値動き範囲:
$19.29
$21.26
1週間の範囲:
$15.13
$21.26
52週間の値動き範囲:
$4.065
$24.00
Bioage Labs Inc Stock (BIOA) Company Profile
Compare BIOA vs TAK, HLN, TEVA, ZTS, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
20.49 | 881.94M | 10.32M | -89.93M | -88.63M | -2.4064 |
TAK
Takeda Pharmaceutical Co Adr
|
15.66 | 49.83B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.09 | 40.04B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 39.23B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
79.33 | 33.52B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
548.27 | 23.33B | 3.17B | 1.29B | 1.01B | 27.09 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-27 | 開始されました | Needham | Buy |
| 2026-02-25 | 開始されました | Oppenheimer | Outperform |
| 2026-02-18 | アップグレード | Jefferies | Hold → Buy |
| 2026-01-27 | 開始されました | Piper Sandler | Overweight |
| 2025-12-05 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2025-10-22 | アップグレード | Citigroup | Neutral → Buy |
| 2025-02-28 | 開始されました | William Blair | Mkt Perform |
| 2024-12-10 | ダウングレード | Morgan Stanley | Overweight → Underweight |
| 2024-12-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-12-09 | ダウングレード | Jefferies | Buy → Hold |
| 2024-10-21 | 開始されました | Citigroup | Buy |
| 2024-10-21 | 開始されました | Jefferies | Buy |
| 2024-10-21 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Bioage Labs Inc (BIOA) 最新ニュース
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus
BIOA News | BIOAGE LABS INC (NASDAQ:BIOA) - ChartMill
BioAge Labs (BIOA) director receives 22,000 stock options at $15.48 strike - Stock Titan
Director at BioAge Labs (BIOA) receives grant of 22,000 stock options - Stock Titan
BioAge Labs (BIOA) director James Healy receives 22,000 stock options at $15.48 - Stock Titan
BioAge Labs (BIOA) director receives grant of 22,000 stock options at $15.48 strike - Stock Titan
BioAge Labs (BIOA) director granted 22,000 stock options at $15.48 strike - Stock Titan
BioAge Labs (BIOA) director awarded 22,000 stock options at $15.48 - Stock Titan
BioAge Labs (NASDAQ: BIOA) shareholders elect directors and ratify KPMG at 2026 meeting - Stock Titan
BIOA Investors Have Opportunity to Lead BioAge Labs, Inc. Securi - GuruFocus
BioAge Labs eyes key BGE-102 readouts in heart risk and diabetic eye disease - MSN
BioAge Labs Eyes Key BGE-102 Readouts in Heart Risk and Diabetic Eye Disease - MarketBeat
BIOA Technical Analysis & Stock Price Forecast - Intellectia AI
BIOA: BGE-102 advances as a differentiated NLRP3 inhibitor with pivotal data expected by year-end - TradingView
BioAge Labs stock gains after positive early data and pipeline plans - MSN
BioAge Labs, Inc.Common Stock (NQ: BIOA - FinancialContent
BIOA Initiated by Roth Capital -- Price Target Set at $36.00 - GuruFocus
Roth Capital Partners Initiates BioAge Labs at Buy With $36 Price Target - marketscreener.com
Roth MKM Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $36 - Moomoo
Roth/MKM initiates BioAge Labs stock coverage with buy rating - Investing.com
Roth/MKM initiates BioAge Labs stock coverage with buy rating By Investing.com - Investing.com India
BIOA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BioAge Labs to Present at Upcoming Investor Conferences - GlobeNewswire
BioAge executives to speak at Jefferies and Goldman healthcare forums - Stock Titan
Is BioAge Labs, Inc. (BIOA) a Top Longevity Biotech Stock to Watch After New Analyst Coverage? - Insider Monkey
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - Benzinga
Shareholders that lost money on BioAge Labs, Inc.(BIOA) should c - GuruFocus
Khosla affiliates hold 1.8M shares in BioAge Labs (NASDAQ: BIOA), 4.0% stake - Stock Titan
Cormorant Asset Management reports 6.51% stake in BioAge Labs (BIOA) - Stock Titan
BioAge Labs, Inc. joins Amgen and Novo Nordisk to outline future obesity drug innovation at Fierce Biotech Week - Traders Union
Number of shareholders of BioAge Labs, Inc. – NASDAQ:BIOA - TradingView
BioAge Labs : BIOA - 24/7 Wall St.
Inside the cell-based Klotho therapy aiming to restore a longevity protein - Stock Titan
BioAge CEO has big plans for 'multi-disease impact' of NLRP3 drug across cardio, ocular and CNS - Fierce Biotech
BTIG initiates coverage of BioAge Labs (BIOA) with buy recommendation - MSN
BTIG Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40 - Moomoo
BioAge Labs, Inc (BIOA) Stock News & Articles - 24/7 Wall St.
Earnings Update: Here's Why Analysts Just Lifted Their BioAge Labs, Inc. (NASDAQ:BIOA) Price Target To US$53.33 - Yahoo Finance
BTIG Initiates BioAge Labs at Buy With $40 Price Target - marketscreener.com
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Lexeo Therapeutics, Inc. (LXEO) - The Globe and Mail
Earnings Beat: BioAge Labs, Inc. (NASDAQ:BIOA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - simplywall.st
TradingKey - TradingKey
BioAge Labs: Analyst Reiterates Buy on Best-in-Class Potential of Lead NLRP3 Inhibitor BGE-102 After Encouraging Phase 1/2 Data - TipRanks
Needham Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $50 - Moomoo
BioAge Labs Releases Q1 2026 Financial Results - AlphaStreet
BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials - Barchart.com
BioAge Labs 1Q Research and Development Expenses Approximately $20.4M >BIOA - Moomoo
BioAge Labs, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioAge Labs 1Q Loss/Shr 52c >BIOA - Moomoo
BioAge Labs Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com
BioAge Labs Reports Positive Phase 1 Results for BGE-102 and Plans Upcoming Clinical Trials in Cardiovascular Risk and Diabetic Macular Edema - Quiver Quantitative
Bioage Labs Inc (BIOA) 財務データ
収益
当期純利益
現金流量
EPS
Bioage Labs Inc (BIOA) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Option Exercise |
5.05 |
8,820 |
44,572 |
8,820 |
| RUBIN PAUL D | Chief Medical Officer |
Apr 01 '26 |
Sale |
17.81 |
8,820 |
157,084 |
0 |
2.11%
大文字化:
|
ボリューム (24 時間):